In-stent restenosis remains a common and important complication after endovascular treatment of superficial femoral artery peripheral artery disease. It occurs in 14 to 35% of cases in 1 year and there is still no efficient treatment for this condition. Paclitaxel-coated balloons have shown promising results.
Objective
Investigate the 3 year results of superficial femoral artery in-stent restenosis treated with paclitaxel-coated balloon angioplasty, using the Lutonix™ 035 device.
Methods
We conducted a retrospective observational study with patients with symptomatic (Rutherford 2 to 5) superficial femoral artery in-stent restenosis, that were treated with paclitaxel-coated balloon angioplasty using the Lutonix™ 035 device, in a single center from January 2016 to December 2020. Duplex scan was used to follow the patients. Primary patency was obtained through Kaplan-Meier analysis. Mortality, and amputation rates were also evaluated.
Results
105 patients were included. Two patients had technical failure and required an additional stent, and were thus excluded. 103 patients were analyzed. Primary patency was 91.26, 80.47, and 67.71%, respectively, in the first, second, and third year after the procedure. There were no deaths 30 days after the procedure. There were no major amputations during the 3 year follow-up.
Conclusion
Paclitaxel-coated balloon angioplasty with the Lutonix™ 035 device was a safe and effective treatment to superficial femoral artery in-stent restenoses. The results were maintained along the 3 year follow-up.
AboyansVRiccoJBBartelinkMLEL, et al.20172017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095
2.
NorgrenLHiattWRDormandyJaNehlerMRHarrisKaFowkesFGRTASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl l):S5-S67. (Tasc Ii). doi:10.1016/j.jvs.2006.12.037
3.
ConteMSBradburyAWKolhP, et al.Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6):3S-125S.e40. doi:10.1016/j.jvs.2019.02.016
4.
BagueNJuliaPSAuguetA, et al.Femoropopliteal in-stent restenosis repair: Midterm outcomes after paclitaxel eluting balloon use (PLAISIR Trial). Eur J Vasc Endovasc Surg. 2017;53(1):106-113. doi:10.1016/j.ejvs.2016.10.002
HoKJOwensCD. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis. J Vasc Surg. 2017;65(2):545-557. doi:10.1016/j.jvs.2016.09.031
7.
VarelaDLArmstrongEJ. Endovascular management of femoropopliteal in-stent restenosis: A systematic review. Cardiovasc Revascularization Med. 2019;20(10):915-925. doi:10.1016/j.carrev.2018.10.028
8.
SixtSCarpio CancinoOGTreszlA, et al.Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58(3):682-686. doi:10.1016/j.jvs.2013.02.019
9.
VirgaVStabileEBiaminoG, et al.Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7(4):411-415. doi:10.1016/j.jcin.2013.11.020
10.
RosenfieldKJaffMRWhiteCJ, et al.Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145-153. doi:10.1056/NEJMoa1406235
11.
LiistroFAngioliPPortoI, et al.Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: The DEBATE-ISR study. J Endovasc Ther. 2014;21(1):1-8. doi:10.1583/13-4420R.1
12.
StabileEVirgaVSalemmeL, et al.Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60(18):1739-1742. doi:10.1016/j.jacc.2012.07.033
13.
KrankenbergHTüblerTIngwersenM, et al.Drug-Coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: The randomized femoral artery in-stent restenosis (FAIR) trial. Circulation. 2015;132(23):2230-2236. doi:10.1161/CIRCULATIONAHA.115.017364
14.
ThiemeMvon BilderlingPPaetzelCKarnabatidisDPerez DelgadoJLichtenbergMLutonix Global SFA Registry Investigators. The 24-Month Results of the Lutonix Global SFA Registry: Worldwide experience with lutonix drug-coated balloon. JACC Cardiovasc Interv. 2017;10(16):1682-1690. doi:10.1016/j.jcin.2017.04.041
15.
von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJPSTROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
16.
BarilDTRheeRYKimJMakarounMSChaerRAMaroneLK. Duplex criteria for determination of in-stent stenosis after angioplasty and stenting of the superficial femoral artery. J Vasc Surg. 2009;49(1):133-138. doi:10.1016/j.jvs.2008.09.046
17.
WainRABerdejoGLDelvalleWN, et al.Can duplex scan arterial mapping replace contrast arteriography as the test of choice before infrainguinal revascularization?J Vasc Surg. 1999;29(1):100-107. doi:10.1016/S0741-5214(99)70352-6
18.
TosakaASogaYIidaO, et al.Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59(1):16-23. doi:10.1016/j.jacc.2011.09.036
19.
KinstnerCMLammerJWillfort-EhringerA, et al.Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-Year results of the PACUBA Trial. JACC Cardiovasc Interv. 2016;9(13):1386-1392. doi:10.1016/j.jcin.2016.04.012
20.
ÖzpakBCayirMC. Drug-eluting balloon treatment in femoropopliteal in-stent restenosis of different lengths. Turk Gogus Kalp Damar Cerrahisi Derg. 2020;28(3):460-466. doi:10.5606/tgkdc.dergisi.2020.18980.
21.
OliveiraJCPPeclatAPRMBarretoFTR, et al.O uso do balão com paclitaxel no tratamento da reestenose intra-stent no segmento fêmoro-poplíteo. J Vasc Bras. 2017;16(1):31-34. doi:10.1590/1677-5449.010616
22.
BrodmannMKeirseKScheinertD, et al.Drug-Coated balloon treatment for femoropopliteal artery disease: The IN.PACT global study de novo in-stent restenosis imaging cohort. JACC Cardiovasc Interv. 2017;10(20):2113-2123. doi:10.1016/j.jcin.2017.06.018
23.
YahagiKOtsukaFSakakuraK, et al.Pathophysiology of superficial femoral artery in-stent restenosis. J Cardiovasc Surg. 2014;55(3):307-323.
24.
KatsanosKSpiliopoulosSKitrouPKrokidisMParaskevopoulosIKarnabatidisD. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb Ischemia: A systematic review and meta-analysis of randomized controlled trials. J Vasc Intervent Radiol. 2020;31(2):202-212. doi:10.1016/j.jvir.2019.11.015
25.
NordanstigJJamesSAnderssonM, et al.Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med. 2020;383(26):2538-2546. doi:10.1056/NEJMoa2005206
26.
LoweryAJHynesNManningBJMahendranMTawfikSSultanS. A prospective feasibility study of duplex ultrasound arterial mapping, digital-subtraction angiography, and magnetic resonance angiography in management of critical lower limb Ischemia by endovascular revascularization. Ann Vasc Surg. 2007;21(4):443-451. doi:10.1016/j.avsg.2006.08.005
